- Home
- FOFO vs HURA Comparison
FOFO vs HURA Comparison
Compare FOFO & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | FOFO | HURA |
|---|---|---|
| Founded | 2017 | 2009 |
| Country | Hong Kong | United States |
| Employees | N/A | 19 |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.2M | 87.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | FOFO | HURA |
|---|---|---|
| Price | $3.85 | $2.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 39.1K | ★ 2.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.09 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.86 | $0.41 |
| 52 Week High | $68.00 | $4.41 |
Technical Indicators
Market Signals| Indicator | FOFO | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 46.02 | 75.81 |
| Support Level | $2.86 | $1.56 |
| Resistance Level | $6.40 | $2.16 |
| Average True Range (ATR) | 0.43 | 0.21 |
| MACD | 0.18 | 0.04 |
| Stochastic Oscillator | 87.77 | 97.13 |
Price Performance
Historical ComparisonAbout FOFO Hang Feng Technology Innovation Co. Ltd. Ordinary Shares
Hang Feng Technology Innovation Co Ltd is committed to providing comprehensive corporate management consulting and asset management services, tailored to address the specific needs of each client. Its goal is to empower its clients to design, implement, and achieve their unique business and investment objectives. Its business consists of two main segments: (i) corporate management consulting services and (ii) asset management services. The corporate management consulting services include Management consulting, and Regulatory compliance and governance consulting.
About HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.